204 related articles for article (PubMed ID: 29657587)
41. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari B; Subramanian L
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
[TBL] [Abstract][Full Text] [Related]
42. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
[TBL] [Abstract][Full Text] [Related]
43. Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
Babalis D; Tritakis V; Floros G; Mouzarou A; Kafkas N; Bampali K; Mertzanos G
Hellenic J Cardiol; 2015; 56(3):237-41. PubMed ID: 26021246
[TBL] [Abstract][Full Text] [Related]
44. Dispersion of QT interval in premature ventricular beats as a marker of susceptibility to arrhythmic events.
Dabrowski A; Kramarz E; Piotrowicz R
J Cardiovasc Risk; 1998 Apr; 5(2):97-101. PubMed ID: 9821062
[TBL] [Abstract][Full Text] [Related]
45. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.
Song Y; Shryock JC; Wu L; Belardinelli L
J Cardiovasc Pharmacol; 2004 Aug; 44(2):192-9. PubMed ID: 15243300
[TBL] [Abstract][Full Text] [Related]
46. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
47. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.
De Vecchis R; Ariano C; Giasi A; Cioppa C
Minerva Cardioangiol; 2018 Jun; 66(3):349-359. PubMed ID: 28497941
[TBL] [Abstract][Full Text] [Related]
48. Ranolazine: a new approach to management of patients with angina.
Tafreshi MJ; Fisher E
Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572
[TBL] [Abstract][Full Text] [Related]
49. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
Hilleman DE; Bauman AL
Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
[TBL] [Abstract][Full Text] [Related]
50. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
Kumar K; Nearing BD; Carvas M; Nascimento BC; Acar M; Belardinelli L; Verrier RL
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):796-802. PubMed ID: 19298570
[TBL] [Abstract][Full Text] [Related]
51. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis.
Trivedi C; Upadhyay A; Solanki K
J Arrhythm; 2017 Jun; 33(3):161-166. PubMed ID: 28607609
[TBL] [Abstract][Full Text] [Related]
53. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.
Verrier RL; Silva AF; Bonatti R; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
J Cardiovasc Electrophysiol; 2015 Mar; 26(3):329-35. PubMed ID: 25346368
[TBL] [Abstract][Full Text] [Related]
54. Ranolazine: Drug overview and possible role in primary microvascular angina management.
Cattaneo M; Porretta AP; Gallino A
Int J Cardiol; 2015 Feb; 181():376-81. PubMed ID: 25555283
[TBL] [Abstract][Full Text] [Related]
55. Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
Nanda S; Levin V; Martinez MW; Freudenberger R
Pacing Clin Electrophysiol; 2010 Dec; 33(12):e119-20. PubMed ID: 20345626
[TBL] [Abstract][Full Text] [Related]
56. Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs.
Zhao G; Messina E; Xu X; Ochoa M; Serpillon S; Shryock J; Belardinelli L; Hintze TH
Eur J Pharmacol; 2006 Jul; 541(3):171-6. PubMed ID: 16777088
[TBL] [Abstract][Full Text] [Related]
57. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
58. Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels.
Ratte A; Wiedmann F; Kraft M; Katus HA; Schmidt C
Front Pharmacol; 2019; 10():1367. PubMed ID: 32038227
[No Abstract] [Full Text] [Related]
59. Association between air pollution and ventricular arrhythmias in high-risk patients (ARIA study): a multicentre longitudinal study.
Folino F; Buja G; Zanotto G; Marras E; Allocca G; Vaccari D; Gasparini G; Bertaglia E; Zoppo F; Calzolari V; Suh RN; Ignatiuk B; Lanera C; Benassi A; Gregori D; Iliceto S
Lancet Planet Health; 2017 May; 1(2):e58-e64. PubMed ID: 29851582
[TBL] [Abstract][Full Text] [Related]
60. Proarrhythmic effects of intravenous vasopressors.
Tisdale JE; Patel RV; Webb CR; Borzak S; Zarowitz BJ
Ann Pharmacother; 1995 Mar; 29(3):269-81. PubMed ID: 7606074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
